Yuanxing Liu1, Haofeng Ji2, Yu Zhang1, Xiuda Shen2, Feng Gao2, Xiangyi He3, Gabriella A Li2, Ronald W Busuttil2, Vijay K Kuchroo4, Jerzy W Kupiec-Weglinski5. 1. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA; Department of Surgery, Division of Hepatobiliary and Pancreatic Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China. 2. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA. 3. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA; Department of Gastroenterology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. 4. Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA. 5. Dumont-UCLA Transplant Center, Division of Liver and Pancreas Transplantation, Department of Surgery, David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, CA, USA. Electronic address: jkupiec@mednet.ucla.edu.
Abstract
BACKGROUND & AIMS: By binding to T cell immunoglobulin mucin-3 (TIM-3) on activated Th1 cells, galectin-9 (Gal-9) negatively regulates Th1-type alloimmunity. Although T cells contribute to hepatic ischemia-reperfusion injury (IRI), it is unknown whether negative T cell-dependent TIM-3 co-stimulation may rescue IR-stressed orthotopic liver transplants from innate immunity-driven inflammation. METHODS: We used wild type (WT) and TIM-3 transgenic (Tg) mice (C57BL/6) as liver donors and recipients in a clinically-relevant model of hepatic cold storage (20 h at 4°C in UW solution) and syngeneic orthotopic liver transplantation (OLT). RESULTS: Orthotopic liver transplants in WT or TIM-3Tg→TIM-3Tg groups were resistant against IR-stress, evidenced by preserved hepatocellular function (serum ALT levels) and liver architecture (Suzuki's score). In contrast, orthotopic liver transplants in WT or TIM-3Tg→WT groups were susceptible to IRI. TIM-3 induction in circulating CD4+ T cells of the recipient: (1) depressed T-bet/IFN-γ, while amplifying GATA3 and IL-4/IL-10 expression in orthotopic liver transplants; (2) promoted T cell exhaustion (PD-1, LAG-3) phenotype; and (3) depressed neutrophil and macrophage infiltration/function in orthotopic liver transplants. In parallel studies, we documented for the first time that Gal-9, a natural TIM-3 ligand, was produced primarily by and released from IR-stressed hepatocytes, both in vivo and in vitro. Moreover, exogenous recombinant Gal-9 (rGal-9) potentiated liver resistance against IRI by depressing T cell activation and promoting apoptosis of CD4+ T cells. CONCLUSIONS: Harnessing TIM-3/Gal-9 signalling at the T cell-hepatocyte interface facilitates homeostasis in IR-stressed orthotopic liver transplants. Enhancing anti-oxidant hepatocyte Gal-9 potentiates liver IR-resistance. Negative regulation by recipient TIM-3+CD4+ cells provides evidence for cytoprotective functions of a discrete T cell subset, which should be spared when applying T cell-targeted immunosuppression in transplant recipients.
BACKGROUND & AIMS: By binding to T cell immunoglobulin mucin-3 (TIM-3) on activated Th1 cells, galectin-9 (Gal-9) negatively regulates Th1-type alloimmunity. Although T cells contribute to hepatic ischemia-reperfusion injury (IRI), it is unknown whether negative T cell-dependent TIM-3 co-stimulation may rescue IR-stressed orthotopic liver transplants from innate immunity-driven inflammation. METHODS: We used wild type (WT) and TIM-3 transgenic (Tg) mice (C57BL/6) as liver donors and recipients in a clinically-relevant model of hepatic cold storage (20 h at 4°C in UW solution) and syngeneic orthotopic liver transplantation (OLT). RESULTS: Orthotopic liver transplants in WT or TIM-3Tg→TIM-3Tg groups were resistant against IR-stress, evidenced by preserved hepatocellular function (serum ALT levels) and liver architecture (Suzuki's score). In contrast, orthotopic liver transplants in WT or TIM-3Tg→WT groups were susceptible to IRI. TIM-3 induction in circulating CD4+ T cells of the recipient: (1) depressedT-bet/IFN-γ, while amplifying GATA3 and IL-4/IL-10 expression in orthotopic liver transplants; (2) promoted T cell exhaustion (PD-1, LAG-3) phenotype; and (3) depressed neutrophil and macrophage infiltration/function in orthotopic liver transplants. In parallel studies, we documented for the first time that Gal-9, a natural TIM-3 ligand, was produced primarily by and released from IR-stressed hepatocytes, both in vivo and in vitro. Moreover, exogenous recombinant Gal-9 (rGal-9) potentiated liver resistance against IRI by depressing T cell activation and promoting apoptosis of CD4+ T cells. CONCLUSIONS: Harnessing TIM-3/Gal-9 signalling at the T cell-hepatocyte interface facilitates homeostasis in IR-stressed orthotopic liver transplants. Enhancing anti-oxidant hepatocyte Gal-9 potentiates liver IR-resistance. Negative regulation by recipient TIM-3+CD4+ cells provides evidence for cytoprotective functions of a discrete T cell subset, which should be spared when applying T cell-targeted immunosuppression in transplant recipients.
Authors: Haofeng Ji; Yu Zhang; Xiu-da Shen; Feng Gao; Cynthia Y Huang; Catalina Abad; Ronald W Busuttil; James A Waschek; Jerzy W Kupiec-Weglinski Journal: Hepatology Date: 2013-01-18 Impact factor: 17.425
Authors: Laurent Monney; Catherine A Sabatos; Jason L Gaglia; Akemi Ryu; Hanspeter Waldner; Tatyana Chernova; Stephen Manning; Edward A Greenfield; Anthony J Coyle; Raymond A Sobel; Gordon J Freeman; Vijay K Kuchroo Journal: Nature Date: 2002-01-31 Impact factor: 49.962
Authors: Sandra Pommey; Bo Lu; Jennifer McRae; John Stagg; Prue Hill; Evelyn Salvaris; Simon C Robson; Anthony J F d'Apice; Peter J Cowan; Karen M Dwyer Journal: Hepatology Date: 2013-03-14 Impact factor: 17.425
Authors: John A Hansen; Samir M Hanash; Laura Tabellini; Chris Baik; Richard L Lawler; Bryan M Grogan; Barry Storer; Alice Chin; Melissa Johnson; Chee-Hong Wong; Qing Zhang; Paul J Martin; George B McDonald Journal: Biol Blood Marrow Transplant Date: 2013-06-17 Impact factor: 5.742
Authors: C Zhang; Y Zhang; Y Liu; Y Liu; S Kageyama; X-D Shen; F Gao; S Zheng; R W Busuttil; G D Shaw; H Ji; J W Kupiec-Weglinski Journal: Am J Transplant Date: 2017-02-06 Impact factor: 8.086
Authors: Kojiro Nakamura; Shoichi Kageyama; Fady M Kaldas; Hirofumi Hirao; Takahiro Ito; Kentaro Kadono; Kenneth J Dery; Hidenobu Kojima; David W Gjertson; Rebecca A Sosa; Maciej Kujawski; Ronald W Busuttil; Elaine F Reed; Jerzy W Kupiec-Weglinski Journal: J Clin Invest Date: 2020-05-01 Impact factor: 14.808
Authors: Yaochun Wang; Yang Yang; Meng Wang; Shuhong Wang; Jong-Min Jeong; Long Xu; Yankai Wen; Christoph Emontzpohl; Constance Lynn Atkins; Kevin Duong; Nicolas F Moreno; Xiaoyi Yuan; David R Hall; Wasim Dar; Dechun Feng; Bin Gao; Yong Xu; Zoltan Czigany; Sean P Colgan; J Steve Bynon; Shizuo Akira; Jared M Brown; Holger K Eltzschig; Elizabeth A Jacobsen; Cynthia Ju Journal: Sci Transl Med Date: 2021-02-03 Impact factor: 17.956
Authors: Cynthia Ju; Meng Wang; Eunyoung Tak; Boyun Kim; Christoph Emontzpohl; Yang Yang; Xiaoyi Yuan; Huban Kutay; Yafen Liang; David R Hall; Wasim A Dar; J Steve Bynon; Peter Carmeliet; Kalpana Ghoshal; Holger K Eltzschig Journal: J Clin Invest Date: 2021-04-01 Impact factor: 14.808